BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan GG, Ma C, Seow CH, Kroeker KI, Panaccione R. The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. J Can Assoc Gastroenterol 2020;3:234-42. [PMID: 32905124 DOI: 10.1093/jcag/gwz044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Buchner AM, Schneider Y, Lichtenstein GR. Biosimilars in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:45-56. [DOI: 10.14309/ajg.0000000000000844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gomes T, McCormack D, Kitchen SA, Paterson JM, Mamdani MM, Proulx L, Bayliss L, Tadrous M. Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. CMAJ Open 2021;9:E1055-62. [PMID: 34815261 DOI: 10.9778/cmajo.20210091] [Reference Citation Analysis]
4 Luber RP, O'Neill R, Singh S, Sharma E, Cunningham G, Honap S, Meade S, Ray S, Anderson SH, Mawdsley J, Sanderson JD, Samaan MA, Arkir Z, Irving PM. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther 2021;54:678-88. [PMID: 34223654 DOI: 10.1111/apt.16497] [Reference Citation Analysis]
5 Hillhouse E, Mathurin K, Bibeau J, Parison D, Rahal Y, Lachaine J, Beauchemin C. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review. Adv Ther 2021. [PMID: 34780028 DOI: 10.1007/s12325-021-01951-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Viscido A, Latella G. Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of "Non-medical Switch". Dig Dis Sci 2020;65:2737-8. [PMID: 32591967 DOI: 10.1007/s10620-020-06423-y] [Reference Citation Analysis]